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Low-grade inflammation in the liver and adipose tissue drives systemic insulin resistance. Recent
reports, discussed in this Select, identify new pathways used by immune cell populations to modu-
late chronic metabolic inflammation that results from obesity-associated insulin resistance.Photograph of adult schistosomes from the
CDC DPDx image library. Image courtesy of
Donald. A. HarnWhat Do Helmiths and Breast Milk Have in
Common?
Parasitic worms such as helmiths and human breast milk express immunomodu-
latory glycans recently shown to improve glucose tolerance and insulin sensitivity.
During infection with Schistosoma mansoni, parasite eggs trapped in host tissues
initiate a cascade of events that results in attenuated immune responses by the
host (hence prolonged parasite survival). Bhargava et al. (2012) demonstrate that
the LewisX trisaccharide, part of the glycan lacto-N-fucopentaose III (LNFPIII),
that is secreted from a saline-soluble homogenate of helmith eggs or human breast
milk is effective in reducing the chronic inflammation seen in diabetes induced by
a high-fat diet (HFD), thus resulting in improved metabolic function. Specifically,
LNFPIII increases interleukin-10 (Il-10), a cytokine that has been shown to improve
metabolic homeostasis. Mice treated with LNFPIII have less proinflammatory
M1 and more anti-inflammatory M2 macrophage-specific gene expression in
white adipose tissue (WAT), resulting in enhanced insulin signaling, reduced
WAT inflammation, and improved systemic glucose homeostasis. An interesting
observation is that although the immunomodulatory activity of LNFPIII in WAT
is Il-10 dependent, the glycan also has critical Il-10-independent functions. Theauthors show that LNFPIII has beneficial effects in liver because it can protect against diet-induced lipid accumulation and
hepatosteatosis. LNFPIII affects de novo lipogenesis by reducing expression of hepatic lipogenic enzymes, including the
master lipogenic transcription factor SREBP-1C. These effects are Il-10 independent, and the LNFPIII-mediated reduction
is partly driven by the upregulation of the negative SREBP-1C regulator and nuclear receptor FXRa via an ERK-AP1-FXRa
axis. Collectively, LNFPIII treatment shifts the immune profile to an anti-inflammatory state, which warrants further exploration
of its therapeutic potential.
Bhargava et al. (2012). Nat. Med. 18, 1665–1672.Neutrofil elastase is a mediator of the low-
grade inflammation seen in insulin resis-
tance. Image courtesy of Dayoung Oh.The Secret Life of Secreted Elastase
Neutrophils, which comprise about 90% of granulocytes, are enriched in the
adipose of mice fed a HFD. This begs the question, do neutrophils play a role in
initiating the inflammatory cascade seen in obesity? In a series of elegant ex-
periments, Talukdar et al. (2012) show that neutrophils contribute to the etiology
of inflammation-induced insulin resistance and that elastase, a serine protease
secreted by neutrophils, plays a crucial mechanistic role in the process. Indeed,
elastase expression and activity increase in the adipose and liver ofmice, concom-
itant to HFD-induced neutrophil infiltration, and chemical inhibition of the enzyme
improves glucose intolerance, whereas treatment with recombinant elastase
has the opposite effect. Moreover, genetic deletion of elastase in mice results in
substantially higher glucose tolerance and lower fasting insulin concentration in
both liver and adipose tissue, as highlighted by increased levels of insulin receptor
substrate 1 (IRS1) (an interesting twist based on the ability of extracellular neutro-
phil elastase to gain access to the intracellular space andmediate its degradation)
and AKT phosphorylation. The authors next show that the proinflammatory effects
of elastase are dependent on TLR-4 signaling and NFkB activation and suggest
that this actionby secretedelastasepossibly results in recruitment andpolarization
of adipose macrophages (M1) and also, as part of a feed-forward secondary
mechanism, additional neutrophil accumulation. Thus, the secret life of secreted
elastase is revealed, and neutrophils can be added to the list of immune cells
mediating the low-grade inflammation seen in insulin resistance driven by obesity.
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Dual energy X-ray absorptiometry scan shows
that iNKT-deficient mice have significantly
more body fat than wild-type mice, but lean
mass is unchanged. Image courtesy of Linda
Lynch.Multipurpose Natural Killer T Cells
In the management of obesity-induced insulin resistance, adapting proven
therapies for other disorders would be highly desirable. A report by Lynch
et al. (2012) suggests just such an approach. They identify an innate T lympho-
cyte population of invariant natural killer T (iNKT) cells that are protective against
the development of HFD-driven insulin resistance. iNKT cells are enriched in the
fat depots of lean humans, get depleted in obesity, and reappear after bariatric
surgery. Similarly, in the mouse, iNKT are severely depleted in the leptin-
deficient (ob/ob) mouse model, progressively decline to markedly reduced
numbers during HFD feeding, and bounce back when the mice are switched
to a chow diet. The authors show that this unique immune repertoire of fat-
derived iNKT cells produces more anti-inflammatory IL-10 after stimulation
with the prototypical lipid antigen alpha-galactosylceramide (aGC), which is
intriguing because IL-10 promotes a phenotype switch toward the M2 anti-
inflammatory macrophage population. Compelling data from mice with iNKT
cell deficiency show a correlation with increased metabolic syndrome andinsulin resistance that worsens on a HFD and increased M1 macrophage infiltration in the adipose. Interestingly, adoptive
transfer of iNKT cells to obese mice not only improves glucose homeostasis but also triggers significant fat loss. The next
burning question of course is, what is the effect of aGC on the insulin-resistance profile of these mouse models? Indeed,
aGC injection causes a significant decrease in adipose mass and cell size, improves glucose homeostasis, and results in
markedly increased iNKT cell numbers. As aGC is already used as a treatment in multiple cancer settings, and it does not
cause hypoglycemia in the diabetic and euglycemic murine models, it is a matter of time before its effect on humans with
insulin resistance is determined.
Lynch et al. (2012). Immunity 37, 574–587.Finding the Mysterious TLR-4 Ligand
Free fatty acids (FFAs) mediate activation of the TLR-4/NFkB pathway to promote insulin resistance. However, how FFAs
activate TLR-4 has remained elusive. The paper by Pal et al. (2012) addresses this conundrum and suggests that fetuin is
the mysterious ligand. This is intriguing because fetuin, a liver secretory glycoprotein and major carrier of FFAs in the
circulation, has already been labeled as a marker of low-grade metabolic inflammation because it stimulates production of
cytokines and chemokines from adipocytes and macrophages. The authors show that fetuin fits the role of a TLR-4 ligand
because it can recapitulate many of the effects seen previously that linked TLR-4 action to insulin resistance. For example,
mice with fetuin and TLR-4 knockdown or hepatectomized rats (another means for reducing fetuin expression) are protected
from HFD-induced insulin resistance and NFkB activation. Restoring fetuin expression in the knockdown mouse model
results in lipid-induced insulin resistance, whereas infusion of the proinflammatory lipid palmitate, a FFA with maximum
binding to fetuin but not to TLR-4, fails to activate TLR-4 in mice with fetuin knockdown. The authors show that FFA-mediated
activation of TLR-4 and subsequent NFkB phosphorylation requires intact fetuin, and the lipotoxicity-driven insulin resistance
involves not only the presence of FFAs, fetuin, and TLR-4 but also their physical interaction. Indeed, two leucine-rich repeats
on TLR-4 are crucial for fetuin binding, and FFAs induce insulin resistance, whereas the terminal b-galactosidase moiety of
fetuin is the candidate site for TLR-4 binding. Thus, fetuin acts as an adaptor protein and endogenous presenter of FFAs
to TLR-4 and represents a new therapeutic target in the management lipid-induced insulin resistance.
Pal et al. (2012). Nat. Med. 18, 1279–1285.
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